Tag Archives: Quick

FDA gifts Alexion quick OK for Soliris follow-up Ultomiris

Alexion was expecting a decision on its Soliris successor by February, but thanks to a quick review from U.S. regulators, it’s made its way onto 2018’s list of new drug approvals. The agency green-lighted the drug, Ultomiris, last week as a treatment for rare and life-threatening blood disease paroxysmal nocturnal hemoglobinuria. The new and improved… Read More »